CRINETICS PHARMACEUTICALS IN (CRNX) Forecast, Price Target & Analyst Ratings

NASDAQ:CRNX • US22663K1079

Current stock price

34.035 USD
-2.28 (-6.27%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRINETICS PHARMACEUTICALS IN (CRNX).

Forecast Snapshot

Consensus Price Target

Price Target
$86.34
+ 153.67% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$1.27
Revenue Estimate
8.77M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.55%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$86.34
Upside
+ 153.67%
From current price of $34.04 to mean target of $86.34, Based on 22 analyst forecasts
Low
$55.55
Median
$89.76
High
$110.25

Price Target Revisions

1 Month
0.00%
3 Months
5.61%

Price Target Summary

22 Wall Street analysts provided a forecast for the next 12 months for CRNX. The average price target is 86.34 USD. This implies a price increase of 153.67% is expected in the next year compared to the current price of 34.035.
The average price target has been revised upward by 5.61% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CRNX Current Analyst RatingCRNX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

CRNX Historical Analyst RatingsCRNX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
84.55%
CRNX was analyzed by 22 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CRNX.
In the previous month the buy percentage consensus was at a similar level.
CRNX was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-02CitizensMaintains Market Outperform -> Market Outperform
2026-01-12Goldman SachsUpgrade Neutral -> Buy
2026-01-08CitizensMaintains Market Outperform -> Market Outperform
2026-01-06Morgan StanleyMaintains Overweight -> Overweight
2025-11-07CitizensMaintains Market Outperform -> Market Outperform
2025-09-30OppenheimerMaintains Outperform -> Outperform
2025-09-29Leerink PartnersMaintains Outperform -> Outperform
2025-09-29Morgan StanleyMaintains Overweight -> Overweight
2025-09-26JMP SecuritiesMaintains Market Outperform -> Market Outperform
2025-09-26BairdMaintains Outperform -> Outperform
2025-09-26Goldman SachsMaintains Neutral -> Neutral
2025-09-24JP MorganMaintains Overweight -> Overweight
2025-08-11JMP SecuritiesMaintains Market Outperform -> Market Outperform
2025-06-27HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-25StifelInitiate Buy
2025-02-28Citizens Capital MarketsMaintains Market Outperform -> Market Outperform
2025-02-04Wolfe ResearchInitiate Peer Perform
2025-01-22JefferiesUpgrade Hold -> Buy
2025-01-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-16JMP SecuritiesReiterate Market Outperform -> Market Outperform
2024-11-14CitigroupMaintains Buy -> Buy
2024-11-13HC Wainwright & Co.Maintains Buy -> Buy
2024-09-27JMP SecuritiesReiterate Market Outperform -> Market Outperform
2024-09-16Cantor FitzgeraldReiterate Overweight -> Overweight
2024-08-09OppenheimerReiterate Outperform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$1.27
Revenue Estimate
8.77M
Revenue Q2Q
2,329.36%
EPS Q2Q
-21.89%
Number of Analysts
15

Next Earnings Revisions

Revenue (1 Month)
12.77%
Revenue (3 Months)
37.35%
EPS (1 Month)
9.22%
EPS (3 Months)
13.16%

Next Earnings Summary

CRNX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -1.27 USD and the consensus revenue estimate is 8.77M USD.
The next earnings revenue estimate has been revised upward by 37.35% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CRNX revenue by date.CRNX revenue by date.
4.013M
-15.34%		1.039M
-74.11%		7.696M
640.71%		63.312M
722.66%		179.67M
183.79%		426.56M
137.41%		951.73M
123.12%		1.626B
70.85%		2.533B
55.78%		3.443B
35.93%		4.723B
37.18%
EBITDA
YoY % growth
CRNX ebitda by date.CRNX ebitda by date.
-221.51M
-32.72%		-336.069M
-51.72%		-512.879M
-52.61%		-510.391M
0.49%		-437.778M
14.23%		-232.53M
46.88%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
CRNX ebit by date.CRNX ebit by date.
-222.608M
-32.60%		-338.854M
-52.22%		-516.769M
-52.50%		-552.667M
-6.95%		-484.132M
12.40%		-308.48M
36.28%		135.97M
144.08%		629.75M
363.15%		1.367B
117.07%		2.131B
55.89%		3.079B
44.49%
Operating Margin
CRNX operating margin by date.CRNX operating margin by date.
-5,547.17%-32,613.47%-6,714.77%-872.93%-269.46%-72.32%14.29%38.73%53.97%61.89%65.19%
EPS
YoY % growth
CRNX eps by date.CRNX eps by date.
-3.70
-17.83%		-3.71
-0.27%		-4.94
-33.15%		-4.98
-0.75%		-4.27
14.19%		-1.76
58.85%		0.35
119.93%		3.93
1,022.20%		8.37
113.02%		12.64
50.97%		19.88
57.30%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-1.27
-21.89%		-1.27
-3.54%		-1.37
0.52%		-1.42
-10.35%
Revenue
Q2Q % growth		8.77M
2,329.36%		12.286M
1,091.66%		17.099M
11,857.34%		22.322M
262.31%
EBITDA
Q2Q % growth		-109.795M
0.62%		-109.189M
14.18%		-121.372M
13.11%		N/A
EBIT
Q2Q % growth		-133.216M
-19.58%		-135.427M
-4.89%		-149.236M
-4.66%		-147.766M
-10.55%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
18.03%
EPS Next 5 Year
22.83%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
304.35%
Revenue Next 5 Year
202.19%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
16.01%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CRINETICS PHARMACEUTICALS IN / CRNX Forecast FAQ

What is the average price target for CRINETICS PHARMACEUTICALS IN (CRNX) stock?

22 analysts have analysed CRNX and the average price target is 86.34 USD. This implies a price increase of 153.67% is expected in the next year compared to the current price of 34.035.

Can you provide the upcoming earnings date for CRINETICS PHARMACEUTICALS IN?

CRINETICS PHARMACEUTICALS IN (CRNX) will report earnings on 2026-05-06, after the market close.

What are the consensus estimates for CRNX stock next earnings?

The consensus EPS estimate for the next earnings of CRINETICS PHARMACEUTICALS IN (CRNX) is -1.27 USD and the consensus revenue estimate is 8.77M USD.

How many analysts have analysed CRINETICS PHARMACEUTICALS IN (CRNX)?

The number of analysts covering CRINETICS PHARMACEUTICALS IN (CRNX) is 22.